Are benefits of combination of insulin degludec and liraglutide independent of baseline glycated haemoglobin level and duration of type 2 diabetes?
IDegLira effectively lowered HbA1c across a range of measures, implying suitability for patients with either early or advanced T2D.
Derivation of vasculogenic and multipotent pericytes from hPSC can be used for the development of vasculogenic models using multiple vasculogenic cell types for basic research and drug screening and can contribute to angiogenic regenerative medicine.